| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Clinical Investigations |
Section of Cellular and Molecular Physiology, Cellular Endocrinology Branch [Y. W., S. Y., D. L.] and Laboratory of Genetics and Physiology [L. Z., L. H.], National Institute of Diabetes and Digestive and Kidney Diseases, NIH, Bethesda, Maryland 20892-1758
 |
ABSTRACT |
|---|
 Top ABSTRACT INTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
|
INTRODUCTION |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
When rhIGF-I is administered to nude mice with s.c. fibrosarcomas, tumor growth is enhanced, and the latency period for tumor development is shortened (1) . In this study, IGF-I treatment increased circulating levels of IGF-I, and IGF-I levels in the peripheral tissues were presumably increased as well. In other murine cancer models, it has been shown that cancer growth may be retarded by food deprivation, which lowers circulating IGF-I levels. A reversible effect has also been shown by IGF-I treatment of the same food-restricted mice (2) .
Recent epidemiological studies have established a correlation between circulating levels of IGF-I and IGFBP-3 and the relative risk for developing colon, breast, prostate, and lung cancer (3, 4, 5, 6, 7) . Ma et al. (3) reported that higher levels of IGF-I and lower levels of IGFBP-3 are independently associated with an increased risk of colorectal cancer. Hankinson’s results indicated that plasma IGF-I concentrations may help to identify women at high risk of developing breast cancer (4) . Furthermore, in a recent study, subjects with adenomas that were designated as high risk for developing into cancer had significantly higher IGF-I levels and significantly lower IGFBP-3 levels than did subjects with normal colonoscopy examinations or those with adenomas that were designated as low risk (8) . Although a direct causative relationship has not yet been established, these findings have led investigators to question whether circulating levels of IGF-I and IGFBP-3 may indeed play a role in the growth of tumors. In addition, patients with acromegaly who have elevated serum levels of growth hormone and IGF-I may be at increased risk for developing colonic premalignant polyps and cancer (9) .
This study was aimed to specifically determine the role of circulating IGF-I levels in tumor growth and metastasis (i.e., in the absence of alterations in peripheral IGF-I gene expression). To this end, we used the LID mouse model that was created using the Cre-lox/P system (10) . We have shown previously that LID mice exhibit a 75% reduction in circulating IGF-I levels, whereas IGF-I expression in peripheral (nonhepatic) tissues is not different from that in control mice (10) . Murine colon 38 adenocarcinoma tissue fragments were transplanted onto the cecum of LID and control mice at the age of 5–6 weeks. Mice were treated with rhIGF-I or saline for 6 weeks after tumor transplantation. The growth of cecum tumors and the extent of hepatic metastases were measured after 6 weeks of treatment. Interestingly, the incidence of cecum tumor growth and hepatic metastases was significantly higher in control mice, as compared with LID mice treated with saline. Administration of rhIGF-I increased tumor growth and metastases in both control and LID mice. These results suggest that circulating IGF-I levels play an important role in tumor growth.
|
MATERIALS AND METHODS |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
Mouse Model of Colon Carcinoma Growth and Hepatic Metastasis.
Colon 38, a mouse adenocarcinoma created in C57BL/6 mice (kindly provided by Dr. Camalier of the National Cancer Institute, NIH, Frederick, MD) is maintained by serial s.c. inoculation in female C57BL/6 mice. Tumor expansion and processing were performed as described previously (12)
. Colon carcinoma growth and hepatic metastases were evaluated in mice, as described previously (13)
with a slight modification. Briefly, mice were anesthetized by s.c. injection of 2.5% Avertin at a dose of 10 µl/g body weight. The abdominal area was shaved and sterilized, and an incision was made in the middle left abdomen. The cecum was gently exposed, and one piece of the Colon 38 tumor tissue (4 x 4 x 4 mm3 in size and weighing 45 ± 0.68 mg) was sutured on the surface of the cecum using 9-0 sutures (Ethicon, Somerville, NJ). The cecum was then returned to the abdominal cavity. The incision was closed in two layers; the peritoneum and muscle were closed using catgut sutures, and the skin was closed with stainless steel wound clips.
IGF-I Injections.
Starting on the second day after surgery, mice were injected twice daily i.p. with 2 mg/kg of rhIGF-I (Genentech, San Francisco, CA) or with the same volume of saline. Mice were euthanized after 6 weeks of injections, and the cecum and liver were removed. The weight of the cecum tumor and the number of visible hepatic metastatic nodules on the surface of liver were recorded.
RNase Protection Assay.
IGF-IR gene expression levels were determined by RNase Protection Assays in the cecum tumor and in metastatic nodule(s) in the liver. Tissues were homogenized with a Polytron homogenizer (Brinkmann Instruments, Wesbury, NY) in RNazol B reagent (Tel-Test, Inc., Friendswood, TX), and total RNA was isolated according to the manufacturer’s instructions. RNase protection assays were carried out as described previously (10)
. Briefly, 50 µg of total RNA were hybridized overnight at 45°C with 32P-labeled riboprobes for exon 3 of the IGF-IR and ß-actin (Ambion, Austin, TX). Protected bands were denatured and separated on 8% polyacrylamide gels. The resulting gels were dried and exposed to X-Omat MS film overnight. The protected bands corresponding to IGF-IR and ß-actin mRNA were quantified by Phosphorimager (Fuji Film, BSA-1800 II).
Western Blot Analysis.
Tissues were homogenized in lysis buffer [150 mM sodium chloride, 10 mM Tris-HCl (pH 7.4), 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 0.5% NP40, 100 mM sodium fluoride, 10 mM sodium PPi, 10 mM sodium orthovanadate, 2 mM phenylmethylsulfonyl fluoride, protease inhibitors (Roche, Indianapolis, IN) 1 tablet/10 ml buffer]. Samples were solubilized for 30 min on ice, centrifuged at 600 rpm for 20 min at 4°C to remove crude particulate matter, and then centrifuged at 40,000 rpm for 45 min at 4°C in a Beckman Ti-70 rotor. Protein (200 µg) from the resulting supernatants was subjected to 8% SDS-PAGE (Invitrogen, Carlsbad, CA) and transferred to nitrocellulose membranes (Invitrogen). The blots were blocked with 5% insulin-free BSA and incubated with an anti-IGF-IR
antibody (Santa Cruz Biotechnology, Santa Cruz, CA) and followed by secondary peroxidase-conjugated donkey antirabbit antibody (Amersham Pharmacia Biotech, Piscataway, NJ). IGF-IR immunoreactivity was detected by chemiluminescence (New England Nuclear, Boston, MA) and quantified by scanning the radiographs and then analyzing the bands with the MacBas version 2.52 software (Fuji Photo Film USA, Inc.).
Measurement of IGF-I and IGFBP-3.
Serum concentration of IGF-I were measured in duplicates in blood samples of both IGF-I- and saline-treated mice (control and LID) by RIA (National Hormone and Pituitary Program, NIDDK). Sensitivity of the assay was 0.02 ng/ml. IGFBP-3 levels were analyzed using a ligand blot assay as reported previously (14)
with slight modifications. Briefly, 2 µl of serum were electrophoresed through a 4–12% SDS-PAGE (Invitrogen). Proteins were transferred to nitrocellulose membranes (Invitrogen). The blots were incubated overnight in TBS containing 2% of BSA. 1.5 million cpm of 125I-labeled IGF-I were added to each membrane overnight. Blots were washed twice with TBS containing 0.1% Tween 20, twice with TBS, and then exposed to Phosphorimager (Fuji Film BAS-1800 II) for quantification.
Tumor Morphology and Immunohistochemical Staining.
Tumor tissue was removed and fixed in 4% paraformaldehyde. Tissues were then embedded in paraffin, and consecutive 5-µm sections were cut and mounted on glass slides. Sections were stained with H&E. Slides were also prepared on poly-L-lysine coated for immunohistochemical staining. An anti-VEGF rabbit polyclonal antibody, obtained from Santa Cruz Biotechnology, was used at a dilution of 1:150. A rabbit polyclonal antibody (Dako Co., Carpinteria, CA) was used at a 1:250 dilution for factor VIII. Immunoperoxidase staining was performed according to the manufacturer’s recommended protocol (Vector ABC kit; DAB substrate kit; Vector, Inc). For positive controls, human breast cancer sections (provided by the Department of Pathology, NIH, Bethesda, MD) were stained for VEGF as well as factor VIII. Negative controls used all reagents except primary antibodies. The intensity of VEGF staining in tumor cells was graded on a scale of 0 to +3, with 0 indicating no detectable staining and +3 indicating the strongest staining, either on primary tumors (in the cecum) or metastatic tumors (in the liver). Vessel counting was performed as described previously (15)
.
Statistical Analyses.
Differences in mean frequencies of cecum tumor growth, cecum tumor weight, hepatic metastasis, and the number of metastatic nodule(s) were analyzed by 
2 analysis. Differences in mean serum levels of IGF-I, IGFBP-3, and mean vessel counts were analyzed by Student’s t test. SigmaPlot5.0 software was used for all analyses.
|
RESULTS |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
, 25 of 44 control mice (56.8%) had a palpable tumor on the cecum detectable from the fourth week after surgery. In contrast, palpable tumors on the cecum were observed in only 16 of 51 LID mice (31.3%; P < 0.01). The latency period until appearance of a palpable mass was significantly shorter in control mice than that of LID mice (23.1 ± 0.57 days versus 27.4 ± 0.76 days; P < 0.05). Cecum tumors in control mice were significantly larger than those in LID mice (1.57 ± 0.44 g in control mice versus 1.18 ± 0.37 g in LID mice; P < 0.01; Table 1
). Furthermore, the frequency of hepatic metastasis was significantly lower in LID mice, as compared with control mice (31.3% in LID mice versus 44.0% in control mice; P < 0.05; Table 2
). Fewer metastatic nodules were found in the liver of LID mice than in control mice (1.20 ± 0.45 versus 2.18 ± 0.60; P < 0.01; Table 2
).
|
|
and 2
, rhIGF-I administration increased the frequency of cecum tumor growth from 56.8 to 76.7% (P < 0.01) in control mice. In addition, the frequency of hepatic metastasis increased from 44 to 56.5% (P < 0.05) in control mice. In LID mice, rhIGF-I treatment also dramatically increased the frequency of cecum tumor growth and hepatic metastasis from 31.3 to 64.5% (P < 0.01) and from 31.25 to 45% (P < 0.05), respectively. The weight of cecum tumors was significantly increased in response to rhIGF-I in both control and LID mice, as shown in Table 1
. Moreover, rhIGF-I treatment significantly increased the number of hepatic metastatic nodules in control mice, as compared with that in LID mice treated with saline (Table 2)
. The latency period until appearance of a palpable mass after rhIGF-I treatment was significantly shorter in control mice than that of LID mice (21.1 ± 0.31 days versus 24.3 ± 0.46 days; P < 0.05). As shown in Fig. 1
, serum levels of IGF-I in LID were markedly decreased (by 75%) as compared with control mice (Fig. 1A)
. After injection of rhIGF-I, there was an increase in circulating IGF-I in control and LID mice. Similarly, IGFBP-3 levels are markedly reduced in the LID mice (by 60%); however, after rhIGF-I injection, there is an increase in the levels of IGFBP-3 in both control and LID mice.
|
. Compared with panels A, B, and C (Fig. 2)
, most parts of muscularis were still intact in the sample from a tumor obtained from a saline-treated LID mouse (Fig. 2D)
. No obvious ulceration of the mucosa was seen. Extensive necrosis can be seen both in some cecum tumors and liver metastatic tumors. The hepatic metastatic tumor (Fig. 2F)
displayed similar histological characteristics as the primary cecum tumor (based on H&E staining). Tumor cells were immunoreactive for VEGF and were observed surrounding blood vessels. The intensity of VEGF staining was higher in the cecum tumors of control mice than in LID mice (Fig. 3, B versus D)
. Exogenous administration of rhIGF-I increased VEGF expression in both control mice and in LID mice (Fig. 3, A versus B
for control mice; Fig. 3, C versus D
for LID mice, respectively). Areas of neovascularization were found in all cecum tumors but were most frequent at the margins of the invasive tumor and in the central regions of tumor where necrosis can be seen. In correspondence, the vessel count (Fig. 4)
was higher in the cecum tumors of control mice than that of LID mice (19.2 ± 1.01 versus 9 ± 1.00; P < 0.01). IGF-I treatment enhanced vessel count for both control mice (28.5 ± 1.06 versus 19.2 ± 1.01; P < 0.01) and LID mice (20 ± 1.70 versus 9 ± 1.00; P < 0.01).
|
|
|
. Because liver itself does not express detectable levels of IGF-IR, this indicates that the nodules have metastasized from the cecum to the liver. IGF-IR protein levels in cecum tumor tissue did not differ significantly between control and LID groups, treated or untreated with IGF-I (data not shown).
|
|
DISCUSSION |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
When colon 38 adenocarcinoma tissue fragments were transplanted into the cecum of LID and control mice, it became apparent that significantly fewer LID mice developed tumors. Thus, we hypothesize that the lower levels of total circulating IGF-I in LID mice impaired tumor development in these animals. However, we cannot exclude the possibility that parallel reductions in IGFBP-3 or IGFBP-1 levels in LID mice may cause fewer tumors to develop. This possibility appears to be remote, because many studies have shown that IGFBP-3 inhibits tumor growth and increases apoptosis in a manner that is often independent of IGF-I. However, there are also some reports that IGFBP-3 can enhance cellular proliferation (16) .
In the established model of cecum tumor growth and development, liver metastases are normally detected as early as day 21 after transplantation, with a maximum event at about 28 days after tumor transplantation (13) . In preliminary experiments, we determined that 42–48 days after transplantation was the period at which the appearance of liver metastases was maximal (data not shown). Therefore, mice were sacrificed at 42–48 days after tumor transplantation in this study. The transplanted tumors grew and invaded all layers of the cecum and colon from the exterior through to the mucosal wall. Interestingly, in addition to the finding that LID mice developed fewer tumors, the sizes of the tumors that did develop were significantly smaller than those seen in control mice. The latency period until a palpable mass was detected was significantly shorter in control compared with LID mice. These observations suggest that the total serum IGF-I levels might affect the rate of tumor growth. Similar to the development of cecal tumors, the presence of visible metastases on the surface of liver occurred at a significantly lower rate in LID mice than in control mice. Importantly, the number of liver metastatic nodules was also lower in LID mice, as compared with control mice. These data suggest that circulating IGF-I levels have independent effects on the metastatic potential.
All cecum tumor specimens and liver metastases expressed IGF-IR mRNA, although rhIGF-I administration did not alter the expression levels of IGF-IR protein. Thus, the biological effect of circulating IGF-I on the tumors may indeed be mediated via the IGF-I receptor expressed on these tumors.
Previous studies have demonstrated that rhIGF-I administration to animals harboring tumors shortens the latency period for the appearance of microscopic tumors and enhances the growth rate of tumors that are already apparent in these animals (1 , 2) . Such studies led investigators to conclude that exogenous administration of IGF-I mediates tumor growth (1 , 2) . In the present study, rhIGF-I administration to both LID and control mice increased serum levels of IGF-I and subsequently increased the incidence of cecal tumor development, primary tumor size, and the number of mice demonstrating liver metastases. In the control mice, rhIGF-I treatment also increased the number of metastatic nodules observed. We propose that circulating IGF-I may be directly involved in tumor growth and metastases, at least in this model. On the other hand, there is no compelling evidence from these or other studies to suggest that the IGFs, IGFBPs, or their receptors are oncogenic, i.e., capable of initiating tumor development.
Tumor growth is the outcome of two opposing forces: cellular proliferation, which increases cell number; and apoptosis, which reduces cell number. IGF-I, the IGFBPs, and the activated IGF-IR are ultimately involved in both of these processes. IGF-I enhances cellular proliferation mainly via activation of mitogen-activated protein kinase, phosphoinositide 3'-kinase, and other pathways, depending on the specific cell type. In all cell types, IGF-I enhances progression of the cell cycle. IGF-I can also exert its mitogenic effects by increasing the expression of mRNA or mRNA stabilization of potent growth factors, such as VEGF (17, 18, 19) . On the other hand, IGF-I potently inhibits apoptosis, through the phosphoinositide 3'-kinase and mitogen-activated protein kinase pathways. Thus, a reduced level of circulating IGF-I in the LID mice may favor conditions that permit apoptosis and oppose the proliferation of tumor cells. Conversely, the administration of exogenous rhIGF-I could shift the equilibrium toward promoting cellular proliferation and opposing apoptosis. Additionally, the elevated serum IGFBP-3 is capable of prolonging the half-life of IGF-I in serum, thereby facilitating IGF-I bioavailability. With regard to the metastatic potential of these tumors, our results show clearly that there is a positive correlation between primary tumor size and the potential for development of metastases. Metastatic processes are still largely undefined. Local metastases along mechanical pathways may reflect migratory processes, whereas distant metastases are usually blood-borne and/or spread via the lymphatic system. Blood vessel formation within the tumors can permit malignant cells to enter into the general circulation, especially if the endothelium of tumor-associated vessels is defective. This may occur in central regions of the tumor in particular, where hypoxia or overt necrosis is more common. The angiogenic potential of a tumor is often an important factor in both the growth of the tumor and its ability to spread. Growth factors, such as angiogenin and VEGF, play a critical role in this process. VEGF is a hypoxia-regulated growth factor involved in angiogenesis and by implication, in tumor growth and metastases. Many tumor cell lines secrete VEGF in vitro, suggesting that this diffusible molecule is a mediator of tumor angiogenesis (20) . VEGF mRNA is markedly up-regulated in the majority of human tumors including lung, breast, and gastrointestinal (21, 22, 23, 24, 25) . Correlations have been documented between VEGF expression and microvessel density in primary breast cancer sections (26) and in gastric carcinoma patients (27) . However, little is known about the role of VEGF in the process of tumor metastasis. Previous studies have demonstrated that IGF-I enhances VEGF gene expression. Therefore, it was of interest to investigate whether the expression of VEGF would be affected by the level of serum IGF-I and whether there is a correlation between the expression and metastasis of VEGF in our model. The cecal tumors from control mice in our study exhibited higher levels of VEGF as compared with tumors from LID mice. IGF-I injection was associated with an increased VEGF expression in tumors from both control and LID mice. These findings support reports of others in which IGF-I has been shown to induce VEGF expression in cultured colorectal carcinoma cells (18) . Our data also indicated that the abundance of vessels in the cecum tumors correlated with the serum levels of IGF-I and the expression of VEGF. Because angiogenesis is associated with VEGF overexpression by tumor cells, we suggest that higher levels of VEGF would result in more vascularization in control mice as compared with LID mice. Higher levels of vascularization, in turn, presumably enable the robust metastatic process to occur as described previously (15) . Thus, up-regulation of VEGF expression by IGF-I may influence tumor cell growth and metastases.
There is a possibility that the effects of IGF-I on tumor growth and metastases may be somehow related to an immunological response. IGF-I has been shown to play a role in proliferation and differentiation of cells from the immune system. Furthermore, Trojan et al. (28) demonstrated that C6 glioma cells expressing antisense IGF-I fail to grow in nude mice and also inhibit the growth of parental C6 glioma cells at a distance. It was suggested that this effect was attributable to an induced immune response via CD8+ lymphocytes. Could the lower levels of IGF-I in our LID mice confer an enhanced immunological response and thereby rejection of the tumor cells? Although this possibility must be considered, it remains entirely speculative at this point. We prefer a more straightforward interpretation of these results as a direct effect of IGF-I on activation of the IGF-IR, rather than an indirect effect on the immune system. Activation of the IGF-IR, in turn, would enhance cellular proliferation and inhibit apoptosis.
In summary, tumor growth and metastasis in mice are regulated by the levels of circulating IGF-I. Higher levels of IGF-I are associated with enhanced tumor development, and lower levels of IGF-I appear to diminish tumor development. The association of serum IGF-I levels with the risk for developing colon cancer in humans is therefore particularly significant, in view of the potential use of rhIGF-I as a therapeutic agent for a number of conditions including diabetes, renal failure, various catabolic syndromes, and age-associated tissue degeneration (29, 30, 31, 32) . In light of these issues, any attempts potentially enhancing serum levels of IGF-I must be approached with caution. However, strategies that are able to inhibit the function of IGF-I receptor by using IGF-IR specific antibody (33, 34) or which are able to lower plasma levels of IGF-I by administrating of antagonists to the growth hormone-releasing hormone (35) or by implementing dietary interventions should be considered with the goal of preventing cancer.
|
ACKNOWLEDGMENTS |
|---|
|
FOOTNOTES |
|---|
1 To whom requests for reprints should be addressed, at Clinical Endocrinology Branch, National Institute of Diabetes and Digestive and Kidney Diseases, NIH, Room 8D12, Building 10, Bethesda, MD 20892-1758. Phone: (301) 496-8090; Fax: (301) 480-4386; E-mail: derek{at}helix.nih.gov 
2 The abbreviations used are: IGF, insulin-like growth factor; IGF-IR, IGF-I receptor; IGFBP, IGF binding protein; rhIGF, recombinant human IGF; LID, liver-specific IGF-I-deficient; VEGF, vascular endothelial growth factor.
Received 5/22/01. Accepted 12/17/01.
|
REFERENCES |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
This article has been cited by other articles:
|
|
 |
|
  T. Moore, L. Beltran, S. Carbajal, S. Strom, J. Traag, S. D. Hursting, and J. DiGiovanni Dietary Energy Balance Modulates Signaling through the Akt/Mammalian Target of Rapamycin Pathways in Multiple Epithelial Tissues Cancer Prevention Research, June 1, 2008; 1(1): 65 - 76. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Moore, S. Carbajal, L. Beltran, S. N. Perkins, S. Yakar, D. LeRoith, S. D. Hursting, and J. DiGiovanni Reduced Susceptibility to Two-Stage Skin Carcinogenesis in Mice with Low Circulating Insulin-Like Growth Factor I Levels Cancer Res., May 15, 2008; 68(10): 3680 - 3688. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Anzo, L. J. Cobb, D. L. Hwang, H. Mehta, J. W. Said, S. Yakar, D. LeRoith, and P. Cohen Targeted Deletion of Hepatic Igf1 in TRAMP Mice Leads to Dramatic Alterations in the Circulating Insulin-Like Growth Factor Axis but Does Not Reduce Tumor Progression Cancer Res., May 1, 2008; 68(9): 3342 - 3349. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Bruel, T. E.H. Christoffersen, and J. R. Nyengaard Growth hormone increases the proliferation of existing cardiac myocytes and the total number of cardiac myocytes in the rat heart Cardiovasc Res, December 1, 2007; 76(3): 400 - 408. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Zimmermann, F. Kiefer, M. Prudenziati, C. Spiller, J. Hansen, T. Floss, W. Wurst, S. Minucci, and M. Gottlicher Reduced Body Size and Decreased Intestinal Tumor Rates in HDAC2-Mutant Mice Cancer Res., October 1, 2007; 67(19): 9047 - 9054. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Colao, R. Pivonello, R. S. Auriemma, M. Galdiero, D. Ferone, F. Minuto, P. Marzullo, and G. Lombardi The Association of Fasting Insulin Concentrations and Colonic Neoplasms in Acromegaly: A Colonoscopy-Based Study in 210 Patients J. Clin. Endocrinol. Metab., October 1, 2007; 92(10): 3854 - 3860. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Xie, Y. Jiang, P. Ouyang, J. Chen, H. Doan, B. Herndon, J. E. Sylvester, K. Zhang, A. Molteni, M. Reichle, et al. Effects of Dietary Calorie Restriction or Exercise on the PI3K and Ras Signaling Pathways in the Skin of Mice J. Biol. Chem., September 21, 2007; 282(38): 28025 - 28035. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Chi-Hang Li and R. Li RAV12 Accelerates the Desensitization of Akt/PKB Pathway of Insulin-like Growth Factor I Receptor Signaling in COLO205 Cancer Res., September 15, 2007; 67(18): 8856 - 8864. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. K. Rowinsky, H. Youssoufian, J. R. Tonra, P. Solomon, D. Burtrum, and D. L. Ludwig IMC-A12, a Human IgG1 Monoclonal Antibody to the Insulin-Like Growth Factor I Receptor Clin. Cancer Res., September 15, 2007; 13(18): 5549s - 5555s. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. de Bono, G. Attard, A. Adjei, M. N. Pollak, P. C. Fong, P. Haluska, L. Roberts, C. Melvin, M. Repollet, D. Chianese, et al. Potential Applications for Circulating Tumor Cells Expressing the Insulin-Like Growth Factor-I Receptor Clin. Cancer Res., June 15, 2007; 13(12): 3611 - 3616. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. A. Samani, S. Yakar, D. LeRoith, and P. Brodt The Role of the IGF System in Cancer Growth and Metastasis: Overview and Recent Insights Endocr. Rev., February 1, 2007; 28(1): 20 - 47. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. W. Allen, C. Saba, E. A. Armstrong, S.-M. Huang, S. Benavente, D. L. Ludwig, D. J. Hicklin, and P. M. Harari Insulin-like Growth Factor-I Receptor Signaling Blockade Combined with Radiation Cancer Res., February 1, 2007; 67(3): 1155 - 1162. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. S.H. Ng, S. Wan, C. W.C. Hui, I. Y.P. Wan, T. W. Lee, M. J. Underwood, and A. P.C. Yim Video-assisted thoracic surgery lobectomy for lung cancer is associated with less immunochemokine disturbances than thoracotomy Eur. J. Cardiothorac. Surg., January 1, 2007; 31(1): 83 - 87. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Sachdev and D. Yee Disrupting insulin-like growth factor signaling as a potential cancer therapy Mol. Cancer Ther., January 1, 2007; 6(1): 1 - 12. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Pacher, M. J. Seewald, M. Mikula, S. Oehler, M. Mogg, U. Vinatzer, A. Eger, N. Schweifer, R. Varecka, W. Sommergruber, et al. Impact of constitutive IGF1/IGF2 stimulation on the transcriptional program of human breast cancer cells Carcinogenesis, January 1, 2007; 28(1): 49 - 59. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Yakar, N. P. Nunez, P. Pennisi, P. Brodt, H. Sun, L. Fallavollita, H. Zhao, L. Scavo, R. Novosyadlyy, N. Kurshan, et al. Increased Tumor Growth in Mice with Diet-Induced Obesity: Impact of Ovarian Hormones Endocrinology, December 1, 2006; 147(12): 5826 - 5834. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. H. Colbert, V. Mai, J. A. Tooze, S. N. Perkins, D. Berrigan, and S. D. Hursting Negative energy balance induced by voluntary wheel running inhibits polyp development in APCMin mice Carcinogenesis, October 1, 2006; 27(10): 2103 - 2107. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Z. Michaylira, J. G. Simmons, N. M. Ramocki, B. P. Scull, K. K. McNaughton, C. R. Fuller, and P. K. Lund Suppressor of cytokine signaling-2 limits intestinal growth and enterotrophic actions of IGF-I in vivo Am J Physiol Gastrointest Liver Physiol, September 1, 2006; 291(3): G472 - G481. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Wang, G. Chakravarty, S. Kim, Y. D. Yazici, M. N. Younes, S. A. Jasser, A. A. Santillan, C. D. Bucana, A. K. El-Naggar, and J. N. Myers Growth-Inhibitory Effects of Human Anti-Insulin-Like Growth Factor-I Receptor Antibody (A12) in an Orthotopic Nude Mouse Model of Anaplastic Thyroid Carcinoma Clin. Cancer Res., August 1, 2006; 12(15): 4755 - 4765. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Pischon, P. H. Lahmann, H. Boeing, C. Friedenreich, T. Norat, A. Tjonneland, J. Halkjaer, K. Overvad, F. Clavel-Chapelon, M.-C. Boutron-Ruault, et al. Body Size and Risk of Colon and Rectal Cancer in the European Prospective Investigation Into Cancer and Nutrition (EPIC). J Natl Cancer Inst, July 5, 2006; 98(13): 920 - 931. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z Attias, H Werner, and N Vaisman Folic acid and its metabolites modulate IGF-I receptor gene expression in colon cancer cells in a p53-dependent manner. Endocr. Relat. Cancer, June 1, 2006; 13(2): 571 - 581. [Abstract] [Full Text] [PDF]
|
|
|
|
|
